Taiwan · Delayed Price · Currency is TWD Lukas Biomedical Statistics
Total Valuation
TPEX:6814 has a market cap or net worth of TWD 900.30 million. The enterprise value is 1.12 billion.
| Market Cap | 900.30M |
| Enterprise Value | 1.12B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6814 has 41.87 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | 41.87M |
| Shares Outstanding | 41.87M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.68% |
| Owned by Institutions (%) | 2.87% |
| Float | 13.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.30 |
| PB Ratio | 4.71 |
| P/TBV Ratio | 4.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.56, with a Debt / Equity ratio of 1.30.
| Current Ratio | 0.56 |
| Quick Ratio | 0.23 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.67 |
| Interest Coverage | -22.35 |
Financial Efficiency
Return on equity (ROE) is -38.79% and return on invested capital (ROIC) is -12.66%.
| Return on Equity (ROE) | -38.79% |
| Return on Assets (ROA) | -11.76% |
| Return on Invested Capital (ROIC) | -12.66% |
| Return on Capital Employed (ROCE) | -28.63% |
| Weighted Average Cost of Capital (WACC) | 4.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 87 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.66 |
Taxes
In the past 12 months, TPEX:6814 has paid 1.87 million in taxes.
| Income Tax | 1.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.69% in the last 52 weeks. The beta is 0.13, so TPEX:6814's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -15.69% |
| 50-Day Moving Average | 24.13 |
| 200-Day Moving Average | 26.73 |
| Relative Strength Index (RSI) | 60.08 |
| Average Volume (20 Days) | 11,636 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6814 had revenue of TWD 170.01 million and -92.05 million in losses. Loss per share was -2.19.
| Revenue | 170.01M |
| Gross Profit | 101.81M |
| Operating Income | -87.17M |
| Pretax Income | -90.18M |
| Net Income | -92.05M |
| EBITDA | -76.22M |
| EBIT | -87.17M |
| Loss Per Share | -2.19 |
Balance Sheet
The company has 26.81 million in cash and 248.75 million in debt, with a net cash position of -221.94 million or -5.30 per share.
| Cash & Cash Equivalents | 26.81M |
| Total Debt | 248.75M |
| Net Cash | -221.94M |
| Net Cash Per Share | -5.30 |
| Equity (Book Value) | 191.26M |
| Book Value Per Share | 4.57 |
| Working Capital | -74.51M |
Cash Flow
In the last 12 months, operating cash flow was -66.75 million and capital expenditures -1.11 million, giving a free cash flow of -67.87 million.
| Operating Cash Flow | -66.75M |
| Capital Expenditures | -1.11M |
| Depreciation & Amortization | 10.96M |
| Net Borrowing | 54.66M |
| Free Cash Flow | -67.87M |
| FCF Per Share | -1.62 |
Margins
Gross margin is 59.88%, with operating and profit margins of -51.27% and -54.14%.
| Gross Margin | 59.88% |
| Operating Margin | -51.27% |
| Pretax Margin | -53.04% |
| Profit Margin | -54.14% |
| EBITDA Margin | -44.83% |
| EBIT Margin | -51.27% |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6814 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | -10.22% |
| FCF Yield | -7.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |